Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.
The FDA has approved datopotamab deruxtecan (Dato-DXd, Datroway, Daiichi Sankyo) for the treatment of patients with ...
The Fracture Risk Assessment Tool predictions suggest patients who don’t meet guideline criteria for parathyroidectomy may ...
Emerging evidence suggests some sugar substitutes may affect metabolism, gut microbiome, and cardiovascular health more than ...
The conditional authorization covers adults and children aged 2 years and older with severe or life-threatening ...
An early evaluation of 'Swap to Stop' scheme in England shows a 4-week quit rate of 34.3% among recipients of free ...
Novel CRISPR-Cas9 treatments are proving effective in reversing disease for life. But ensuring their long-term safety will ...
A cohort study of births in Brazil found increased hospitalization risk through age 3 after maternal chikungunya; results ...
Researchers have identified a compound produced by a variety of land snail that prevents blood clots without prolonging ...
The oral therapy is intended for adults with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis, two fibrotic ...
Dr Sunnie Kim previews key GI trials highlighting novel bispecific antibodies, dual immunotherapy combinations, KIT ...
Higher dermatologist density is associated with lower proportions of late stage melanoma diagnosis across US health service ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results